ATE286741T1 - Glutathioneanaloge enthaltende therapeutische zusammensetzungen - Google Patents
Glutathioneanaloge enthaltende therapeutische zusammensetzungenInfo
- Publication number
- ATE286741T1 ATE286741T1 AT00908420T AT00908420T ATE286741T1 AT E286741 T1 ATE286741 T1 AT E286741T1 AT 00908420 T AT00908420 T AT 00908420T AT 00908420 T AT00908420 T AT 00908420T AT E286741 T1 ATE286741 T1 AT E286741T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions containing
- therapeutic compositions
- containing glutathione
- potentiate
- methods
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000005757 colony formation Effects 0.000 abstract 1
- 230000001066 destructive effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23853099A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/002297 WO2000044366A2 (en) | 1999-01-27 | 2000-01-27 | Therapeutic compositions containing glutathione analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE286741T1 true ATE286741T1 (de) | 2005-01-15 |
Family
ID=22898312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00908420T ATE286741T1 (de) | 1999-01-27 | 2000-01-27 | Glutathioneanaloge enthaltende therapeutische zusammensetzungen |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1143992B1 (https=) |
| JP (2) | JP2002535359A (https=) |
| KR (1) | KR100750842B1 (https=) |
| CN (1) | CN1185008C (https=) |
| AT (1) | ATE286741T1 (https=) |
| AU (1) | AU778340B2 (https=) |
| CA (1) | CA2360795C (https=) |
| DE (1) | DE60017359T2 (https=) |
| ES (1) | ES2231159T3 (https=) |
| HK (1) | HK1043310B (https=) |
| PT (1) | PT1143992E (https=) |
| WO (1) | WO2000044366A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW576838B (en) | 1998-04-16 | 2004-02-21 | Teijin Ltd | Glutathione derivatives and application form thereof |
| US7029695B2 (en) | 2001-07-10 | 2006-04-18 | Telik, Inc. | Therapeutic compositions containing glutathione analogs |
| BRPI0606520A2 (pt) * | 2005-01-06 | 2009-06-30 | Telik Inc | tripeptìdeo e tetrapeptìdeo tioéteres |
| CN101434645B (zh) * | 2008-12-24 | 2013-01-16 | 中国农业大学 | 一种合成寡肽及其用途 |
| AU2012321104A1 (en) * | 2011-12-02 | 2013-06-20 | Telik, Inc. | Amphorous ezatiostat ansolvate |
| CN108863888B (zh) * | 2018-07-18 | 2021-10-12 | 吉尔生化（上海）有限公司 | 一种(s)-1-(叔丁氧羰基)-5-氧吡咯烷-2-羧酸乙酯的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786336A (en) * | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| JP3118869B2 (ja) * | 1991-05-14 | 2000-12-18 | ウェルファイド株式会社 | プロスタグランジン類含有脂肪小体組成物 |
| CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
| JP3383704B2 (ja) * | 1993-04-02 | 2003-03-04 | わかもと製薬株式会社 | 安定なリポソーム水分散液 |
| JPH09504517A (ja) * | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
| JP2891883B2 (ja) * | 1993-11-05 | 1999-05-17 | 学校法人近畿大学 | 抗白内障医薬組成物 |
| JPH11507056A (ja) * | 1995-06-07 | 1999-06-22 | テラピン テクノロジーズ、インク． | グルタチオンアナログの代謝的効果 |
-
2000
- 2000-01-27 AT AT00908420T patent/ATE286741T1/de active
- 2000-01-27 CN CNB008046522A patent/CN1185008C/zh not_active Expired - Fee Related
- 2000-01-27 WO PCT/US2000/002297 patent/WO2000044366A2/en not_active Ceased
- 2000-01-27 ES ES00908420T patent/ES2231159T3/es not_active Expired - Lifetime
- 2000-01-27 AU AU29767/00A patent/AU778340B2/en not_active Ceased
- 2000-01-27 CA CA2360795A patent/CA2360795C/en not_active Expired - Fee Related
- 2000-01-27 PT PT00908420T patent/PT1143992E/pt unknown
- 2000-01-27 KR KR1020017009543A patent/KR100750842B1/ko not_active Expired - Fee Related
- 2000-01-27 HK HK02104871.4A patent/HK1043310B/zh not_active IP Right Cessation
- 2000-01-27 DE DE60017359T patent/DE60017359T2/de not_active Expired - Lifetime
- 2000-01-27 EP EP00908420A patent/EP1143992B1/en not_active Expired - Lifetime
- 2000-01-27 JP JP2000595670A patent/JP2002535359A/ja active Pending
-
2007
- 2007-09-05 JP JP2007229798A patent/JP2007326877A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000044366A2 (en) | 2000-08-03 |
| ES2231159T3 (es) | 2005-05-16 |
| EP1143992A2 (en) | 2001-10-17 |
| DE60017359T2 (de) | 2005-12-01 |
| KR100750842B1 (ko) | 2007-08-22 |
| EP1143992B1 (en) | 2005-01-12 |
| AU778340B2 (en) | 2004-12-02 |
| CN1185008C (zh) | 2005-01-19 |
| DE60017359D1 (de) | 2005-02-17 |
| PT1143992E (pt) | 2005-05-31 |
| HK1043310B (zh) | 2005-10-07 |
| WO2000044366A3 (en) | 2000-12-21 |
| CA2360795A1 (en) | 2000-08-03 |
| JP2007326877A (ja) | 2007-12-20 |
| AU2976700A (en) | 2000-08-18 |
| HK1043310A1 (en) | 2002-09-13 |
| CN1342084A (zh) | 2002-03-27 |
| JP2002535359A (ja) | 2002-10-22 |
| KR20010101775A (ko) | 2001-11-14 |
| CA2360795C (en) | 2010-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2051800T3 (es) | Tableta cubierta de dihidropiridina. | |
| DE60021059D1 (de) | Hydrogelpartikel formulierungen | |
| UY26439A1 (es) | Nueva composición y uso | |
| HRP20041152B1 (hr) | Farmaceutske formulacije | |
| DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| IL153297A0 (en) | Compounds and compositions for delivering active agents | |
| DE60230021D1 (de) | Systeme zur verabreichung eines kosmetischen und/oder therapeutischen wirkstoffes an mundoberflächen | |
| MXPA01008611A (es) | Compuestos y composiciones para suministrar agentes activos. | |
| ES2194720T3 (es) | Enzimas para el tratamiento de diabetes mellitus tipo i. | |
| NO981746D0 (no) | Utlevering av biologisk aktive polypeptider | |
| ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| MX9206577A (es) | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES | |
| NO953278D0 (no) | Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette | |
| MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
| ES2049690T1 (es) | Derivados de taxano, su preparacion y uso en oncologia. | |
| AR047191A1 (es) | Metodos de tratamiento de fibrosis hepatica | |
| ATE287267T1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| EP1962843A4 (en) | USE OF PARP-1 INHIBITORS | |
| ATE286741T1 (de) | Glutathioneanaloge enthaltende therapeutische zusammensetzungen | |
| UY27662A1 (es) | Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny. | |
| IT8021550A0 (it) | Derivati adenosinici ad attivita'antinfiammatoria ed analgesica e composizioni terapeutiche che licontengono come principio attivo. | |
| DK1273301T3 (da) | Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration | |
| MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
| SE0203817D0 (sv) | New composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1143992 Country of ref document: EP |